Samsung Biologics new IPO could be valued at $2.6 billion - Medical Design and Outsourcing
Lucile Plourde-Owobi on LinkedIn: Samsung Biologics invites WHO program trainees for biologics development…
Samsung BioLogics sees sales rise but profit fall as it continues expansion | Fierce Pharma
Samsung Biologics set to start construction of Plant 5
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Milestones | Company | About Us | SAMSUNG BIOLOGICS
Samsung Biologics Speeds Up $1.5 Billion Plant Project Amid mRNA Push - Bloomberg
Covid-19 : Samsung Biologics va produire l'anticorps de Lilly
Samsung Biologics Sets Sights on Net Zero Transition as New Plant Revs Up
Samsung Biologics grabs US$81M contract manufacturing deal with Novartis | HealthCare Middle East & Africa Magazine
Samsung BioLogics: The story of the world's largest biologics manufacturing facility
Samsung Biologics' P4 Super Plant, Songdo, South Korea
Samsung Biologics eyes IPO by year-end - Nikkei Asia
Samsung Biologics finalise un autre contrat très lucratif !
Samsung Biologics mise sur l'industrie pharmaceutique - Le Matin.ma
Samsung Biologics to go big on CDMO at BIO USA 2023
Samsung Biologics | ISM
Samsung Biologics signe un contrat de 411,3 millions de dollars avec Pfizer | AGENCE DE PRESSE YONHAP
Biosimilaires : Biogen se déleste de Samsung Bioepis
Samsung Biologics building 4th plant at $1.5 bn to double bioreactor capacity - Pulse by Maeil Business News Korea
Samsung Biologics boasts top-tier production capacity at BIO International
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics Accelerates Timeline Of New Fifth Plant | Contract Pharma
Company News | Newsroom | SAMSUNG BIOLOGICS
CDMO : Samsung Biologics va produire les biosimilaires de Pfizer
